Market research
9SO.F Solasia Pharma K.K
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 37M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.18
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- JP3436500007
- Market cap
- 37M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.18
About
About Solasia Pharma K.K
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
Research context
Solasia Pharma K.K appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 9SO.F discussion.
5 years, 7 months ago
Solasia Pharma K.K is currently in a long term uptrend where the price is trading 2.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.6.
Solasia Pharma K.K's total revenue sank by 83.6% to $167M since the same quarter in the previous year.
Its net income has dropped by 1023.1% to $-2B since the same quarter in the previous year.
Finally, its free cash flow fell by 212.4% to $-554M since the same quarter in the previous year.
Based on the above factors, Solasia Pharma K.K gets an overall score of 2/5.